Business
Neurochem to Present at Upcoming Healthcare Conferences
Neurochem to Present at Upcoming Healthcare Conferences.
About this update from Bluenergies Ltd.
[{"type":"text","content":"\n\n\n\n\nLAVAL, QC, Nov. 3 /CNW Telbec/ - Neurochem Inc. (NASDAQ: NRMX; TSX: NRM)\nannounced today that on Monday, November 6, 2006, Dr. Francesco Bellini,\nChairman, President and CEO, will present Neurochem's overall strategy and\nprogress to date at the Rodman & Renshaw 8th Annual Healthcare Conference to\nbe held at the New York Palace Hotel, in New York (N.Y.). The presentation\nwill take place at 9:10 A.M. ET, in room Holmes II.\nThe corporate presentation will be available on the Company's Web site at\nhttp://www.neurochem.com/Investor.htm(number sign)Presentation following Dr. Bellini's\nspeech.\nDr. Bellini will also present an update on the Company's activities at\nthe CIBC 17th Annual Healthcare Conference on Monday, November 6, 2006, at the\nWaldorf-Astoria in New York (N.Y.). The presentation will take place at\n3:15 P.M. ET, in the Jade room, and will be available on the Company's\nwebsite.\n\nAbout Neurochem\n\nNeurochem Inc. is focused on the development and commercialization of\ninnovative therapeutics to address critical unmet medical needs. Eprodisate\n(KIACTA(TM); formerly FIBRILLEX(TM)) is currently being developed for the\ntreatment of Amyloid A (AA) amyloidosis, and is under regulatory review for\nmarketing approval by the U.S. Food and Drug Administration and European\nMedicines Agency. Tramiprosate (ALZHEMED(TM)), for the treatment of\nAlzheimer's disease, is currently in Phase III clinical trials in both North\nAmerica and Europe and tramiprosate (CEREBRIL(TM)), for the prevention of\nHemorrhagic Stroke caused by Cerebral Amyloid Angiopathy, has completed a\nPhase IIa clinical trial.\n\nTo Contact Neurochem\n\nFor additional information on Neurochem and its drug development\nprograms, please call the North American toll-free number 1-877-680-4500 or\nvisit our Web Site at www.neurochem.com.\n\nCertain statements contained in this news release, other than statements\nof fact that are independently verifiable at the date hereof, may\nconstitute forward-looking statements. Such statements, based as they are\non the current expectations of management, inherently involve numerous\nrisks and uncertainties, known and unknown, many of which are beyond\nNeurochem's control. Such risks include but are not limited to: the\nimpact of general economic conditions, general conditions in the\npharmaceutical indust...